Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

REMIFENTANIL vs RESLIZUMAB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

REMIFENTANIL vs RESLIZUMAB: Safety Overview

Metric REMIFENTANIL RESLIZUMAB
Total FAERS Reports 2,733 621
Deaths Reported 210 15
Death Rate 7.7% 2.4%
Hospitalizations 995 121
Average Patient Age 50.3 yrs 55.9 yrs
% Female Patients 48.2% 63.2%
FDA Approval Date Jan 16, 2018 N/A
Manufacturer Fresenius Kabi USA, LLC Teva Respiratory, LLC
Route INTRAVENOUS INTRAVENOUS
Marketing Status Prescription Prescription